メールサービス キャンペーン : 期間中に新規登録や配信希望カテゴリの変更等をされた方に、ご用意した無料レポートを提供しております。 新規登録 / 登録内容変更

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

過敏症:世界の治験レビュー

Hypersensitivity Global Clinical Trials Review, H2, 2017

発行 GlobalData 商品コード 318340
出版日 ページ情報 英文 536 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.61円で換算しております。
Back to Top
過敏症:世界の治験レビュー Hypersensitivity Global Clinical Trials Review, H2, 2017
出版日: 2017年10月31日 ページ情報: 英文 536 Pages
概要

当レポートでは、過敏症(感受性亢進)に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、主な先進国・新興国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んでお届けいたします。

目次

  • イントロダクション
    • 過敏症
    • 当レポートの概要
  • 地域別の治験状況
    • 各国の治験件数と平均被験者数
      • アジア太平洋地域の主要5ヶ国における治験件数
      • 欧州の主要5ヶ国における治験件数
      • 北米の主要国における治験件数
      • 中東・アフリカの主要5ヶ国における治験件数
      • 中南米の主要国における治験件数
  • G7諸国での治験件数:免疫疾患治療薬の治験における過敏症の割合
  • G7諸国での治験件数:フェーズ(相)別
  • G7諸国での治験件数:進捗状況別
  • E7諸国での治験件数:免疫疾患治療薬の治験における過敏症の割合
  • E7諸国での治験件数:フェーズ(相)別
  • E7諸国での治験件数:進捗状況別
  • フェーズ(相)別の治験件数
    • 進行中の治験:フェーズ別
  • 進捗状況別の治験件数
  • 治験の目標の達成状況
  • 未完了の治験件数:過敏症の場合
  • 一定期間に採用された被験者
  • スポンサーの種類別の治験件数
  • 有望なスポンサー
    • 過敏症の治療薬の治験に携わっている主要企業
  • 有望な薬剤
  • 治験のプロファイル
    • 主要企業の治験の概要
      • Allergy Therapeutics plc
      • GlaxoSmithKline plc
      • Merck & Co., Inc.
      • 小野薬品工業
      • Laboratorios LETI S.L.
      • United Pharmaceuticals SA
      • Sanofi
      • Procter & Gamble Srl
      • Noblewell, Inc
      • Allertein Therapeutics, LLC
    • 主要研究機関/政府の治験の概要
      • The National Institute of Allergy and Infectious Diseases
      • The University of North Carolina at Chapel Hill
      • Assistance Publique - Hopitaux de Paris
      • Maastricht University Medical Center
      • University Hospital Inselspital, Berne
      • Imperial College London
      • The Children's Hospital of Philadelphia
      • Isfahan University of Medical Sciences
      • Chinese University of Hong Kong
      • National Institute of Neurological Disorders and Stroke
  • 5つの代表的な治験のプロファイル
  • 付録

図表一覧

目次
Product Code: GDHC4621CTIDB

GlobalData's clinical trial report, "Hypersensitivity Global Clinical Trials Review, H2, 2017" provides an overview of Hypersensitivity clinical trials scenario. This report provides top line data relating to the clinical trials on Hypersensitivity. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Hypersensitivity to Immunology Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Hypersensitivity to Immunology Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 20
  • Clinical Trials in E7 Countries by Trial Status 21
  • Clinical Trials by Phase 22
  • In Progress Trials by Phase 23
  • Clinical Trials by Trial Status 24
  • Clinical Trials by End Point Status 26
  • Subjects Recruited Over a Period of Time 27
  • Clinical Trials by Sponsor Type 28
  • Prominent Sponsors 29
  • Top Companies Participating in Hypersensitivity Therapeutics Clinical Trials 31
  • Prominent Drugs 33
  • Clinical Trial Profile Snapshots 34

Appendix 534

  • Abbreviations 534
  • Definitions 534
  • Research Methodology 535
  • Secondary Research 535
  • About GlobalData 536
  • Contact Us 536
  • Source 536

List of Tables

List of Tables

  • Hypersensitivity Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Hypersensitivity Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Hypersensitivity Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Hypersensitivity Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
  • Hypersensitivity Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
  • Hypersensitivity Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
  • Hypersensitivity Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 14
  • Hypersensitivity Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 15
  • Proportion of Hypersensitivity to Immunology Clinical Trials, G7 Countries (%), 2017* 16
  • Hypersensitivity Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Hypersensitivity Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Hypersensitivity to Immunology Clinical Trials, E7 Countries (%), 2017* 19
  • Hypersensitivity Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Hypersensitivity Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Hypersensitivity Therapeutics, Global, Clinical Trials by Phase, 2017* 22
  • Hypersensitivity Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
  • Hypersensitivity Therapeutics, Global, Clinical Trials by Trial Status, 2017* 25
  • Hypersensitivity Therapeutics Clinical Trials, Global, by End Point Status, 2017* 26
  • Hypersensitivity Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 27
  • Hypersensitivity Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 28
  • Hypersensitivity Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 30
  • Hypersensitivity Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 32
  • Hypersensitivity Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 33

List of Figures

List of Figures

  • Hypersensitivity Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Hypersensitivity Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Hypersensitivity Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Hypersensitivity Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
  • Hypersensitivity Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
  • Hypersensitivity Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
  • Hypersensitivity Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 14
  • Hypersensitivity Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017* 15
  • Proportion of Hypersensitivity to Immunology Clinical Trials, G7 Countries (%), 2017* 16
  • Hypersensitivity Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Hypersensitivity Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Hypersensitivity to Immunology Clinical Trials, E7 Countries (%), 2017* 19
  • Hypersensitivity Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Hypersensitivity Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Hypersensitivity Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
  • Hypersensitivity Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
  • Hypersensitivity Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Hypersensitivity Therapeutics Clinical Trials, Global, by End Point Status, 2017* 26
  • Hypersensitivity Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 27
  • Hypersensitivity Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 28
  • Hypersensitivity Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 29
  • Hypersensitivity Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31
  • Hypersensitivity Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 33
  • GlobalData Methodology 535
Back to Top